Cambridge, United Kingdom
Horizon Discovery, founded in 2005 and headquartered in the United Kingdom, is a leading player in the field of gene editing and gene modulation. Formerly part of PerkinElmer and currently integrated into the Revvity family, Horizon empowers a broad range of sectors, including academic research, pharmaceuticals, biotechnology, and clinical diagnostics, with cutting-edge technologies.
Under the banner of their slogan, "On the path from research to therapy – Inspired Cell Solutions," the company leverages a decade-plus of experience to engineer cell lines. This expertise underpins their capability to modulate or permanently alter gene functions in human and other mammalian cell lines, supporting the identification of genetic disease drivers, diagnostic development, and therapeutic advancement.
Their recent acquisition by PerkinElmer Ventures for $383.00M in November 2020 indicates strong investor confidence. With offices in the USA and Japan, Horizon Discovery is strategically positioned for continued growth in precision medicine.
